Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 4Leukemia, Myeloid, Acute 3Lymphoma, Non-Hodgkin 2Carcinoma, Basal Cell 2Breast Diseases 2Basal Cell Nevus Syndrome 2Upper Tract Urothelial Carcinomas 1Thrombocythemia, Essential 1Solid Tumors 1Serous Ovarian Cancer 1Recurrence 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Polycythemia Vera 1Ovarian Neoplasms 1Lymphedema 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hypogonadism 1Glioma 1Gastric Adenocarcinoma 1Fatigue Syndrome, Chronic 1Eunuchism 1Colorectal Neoplasms 1Amyloidosis 1Adenoma 1

Interventions

Temozolomide 156Bevacizumab 69Radiotherapy 61Magnetic Resonance Spectroscopy 59Irinotecan 31Surgical Procedures, Operative 23Radiation 23Carboplatin 23Specimen Handling 20Carmustine 20Nivolumab 19Biopsy 17Lomustine 15Aminolevulinic Acid 15Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12pembrolizumab 12Radiosurgery 12Erlotinib Hydrochloride 12fluorodopa F 18 11Topotecan 11Everolimus 11Blood Specimen Collection 11X-Rays 10IL13-PE38 10dabrafenib 9Etoposide 9ribociclib 8poly ICLC 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioma × Drug Evaluation × Clear all
NCT01403610 2019-07-24

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
28 enrolled 9 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡